Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: annexonbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/1/2024 | $11.00 | Neutral → Overweight | JP Morgan |
| 12/21/2023 | $4.00 → $6.00 | Neutral → Buy | BofA Securities |
| 10/30/2023 | $11.00 | Overweight | Wells Fargo |
| 5/26/2023 | $8.00 → $3.00 | Buy → Neutral | BofA Securities |
| 5/25/2023 | $19.00 → $9.00 | Overweight → Neutral | JP Morgan |
| 9/16/2022 | $12.00 | Buy | Jefferies |
| 9/9/2022 | $15.00 | Buy | BTIG Research |
| 11/30/2021 | $40.00 | Buy | HC Wainwright & Co. |
| 9/23/2021 | $40.00 | Overweight | Cantor Fitzgerald |